DATE: June 27, 2018

TO: AHCCCS Contractors
AHCCCS Registered Providers

FROM: Sara Salek, MD, AHCCCS Chief Medical Officer
Suzanne Berman, RPh, AHCCCS Pharmacy Director

SUBJECT: Buprenorphine Use in Pregnant and Nursing Women for Medication Assisted Therapy (MAT).

Effective July 1, 2018, prior authorization is not required for buprenorphine, without naloxone, for MAT use by women who are pregnant and/or nursing. The pharmacy may adjudicate the prescription claim with the pharmacy benefit manager (PBM) at the point-of-sale when the Prescribing Clinician indicates one of the following ICD-10 Codes on the prescription*:

- O09.91 - Supervision of high risk pregnancy, 1st trimester
- O09.92 - Supervision of high risk pregnancy, 2nd trimester
- O09.93 - Supervision of high risk pregnancy, 3rd trimester
- O09.90 - Supervision of high risk pregnancy - use for post-partum nursing mothers.

*The Prescribing Clinician must write the ICD-10 code on the hard copy prescription or communicate the coding telephonically, electronically or via fax to the pharmacy. The pharmacy must enter the diagnostic code in the NCPDP fields below prior to adjudicating the claim with the PBM:

- NCPDP Field 492-WE: enter 02
- NCPDP Field 424-DO: enter the ICD-10 diagnostic code provided and/or communicated by prescribing clinician to the pharmacy.

As a reminder, the Pharmacy Help Desks of the PBMs for the AHCCCS Fee-For-Service Program and the AHCCCS Contracted Managed Care Organizations will only be able to assist with the claim adjudication process; all questions regarding the ICD-10 Code must be directed back to the Prescribing Clinician.

For questions, you may contact Suzi Berman at 602-417-5726 or you may submit an email to AHCCCSPharmacyDept@azahcccs.gov.